References
- Lindberg G. Omeprazole versus ranitidine in reflux oesophagitis in Sweden. PharmacoEconomics 1994; 5 Suppl. 3: 27–34
- Jönsson B, Stålhammar N O. The cost effectiveness of ome-prazole and ranitidine in intermittent and maintenance treatment of reflux oesophagitis—the case of Sweden. Br J Med Econ 1993; 6: 111–26
- Hillman A L, Bloom B S, Fendrick A M, Schwartz J S. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med 1992; 152: 1467–72
- Bate C M. Omeprazole versus ranitidine and cimetidine in reflux oesophagitis. Br perspective. PharmacoEconomics 1994; 5 Suppl 3: 35–43
- Bloom B S, Hillman A L, LaMont B, Liss C, Schwartz J S, Stever G J. Omeprazole or ranitidine plus metetoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysis. PharmacoEconomics 1995; 8(4)343–9
- Culyer A J, Maynard A. Cost-effectiveness of duodenal ulcer treatment. Soc Sci Med 1981; 15C: 3–11
- Geweke J, Weisbrod B. Assessing technological change: the case of a new drug. University of Wisconsin, Madison 1982
- Geweke J, Weisbrod B. How does technological change affect health care expenditures? The case of a new drug. Eval Rev 1984; 8: 75–92
- Sintonen H, Alander V. Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers. J Health Econ 1990; 9: 85–101
- Sonnenberg A. Costs of medical and surgical treatment of duodenal ulcer. Gastroenterology 1989; 96: 1445–52
- Walan A, Eriksson S. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole and ranitidine for healing of duodenal ulcer. Scand J Gastroenterol 1994; 29 Suppl. 201: 91–7
- Jönsson B, Drummond M F, Stålhammar N O. Cost-effectiveness of omeprazole and ranitidine in the treatment of duodenal ulcer. PharmacoEconomics 1994; 5 Suppl 3: 44–5
- Unge P, Jönsson B, Stålhammar N O. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. Pharmacoeconomics 1995; 8: 410–27
- O'Brien B, Goeree R, Mohamed A H, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958–64
- Jönsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996; 215(30 Suppl, 31 Suppl)90–5
- Fennerty B. 'Cure' of Helicobacter pylori. Arch Intern Med 1995; 135
- Jönsson B, Haglund U. Cost-effectiveness of misprostol in Sweden. Jnl J Technol Assess Health Care 1992; 8: 234–44
- Stucki G, Johannesson M, Liang H. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis?. Arch Intern Med 1994; 154: 2020–5
- Weller D, Moss J, Hiller J, Thomas D, Edwards J. Screening for colorectal cancer: What are the costs?. Int J Tech Assess Health Care 1995; 11(1)26–39
- Shimbo T, Glick H A, Eisenberg J M. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Tech Assess Health Care 1994; 10(3)359–75
- Blumenthal I S. Research and the ulcer problem. Rand Corporation, Santa Monica 1959
- Blumenthal I S. Digestive disease as a national problem. Gastroenterology 1968; 54: 86–92
- Weisbrod B A. Economic approaches to evaluating a new medical technology: the drug cimetidine. Economic and medical evaluation of health care technologies, Culyer, Horisberger. Springer Verlag, Berlin 1983; 188–205
- Jönsson B. A review of the macroeconomic evaluation of cimetidine. Economic and medical evaluation of health care technologies, Culyer, Horisberger. Springer Verlag, Berlin 1983; 241–261
- Bodemar G, Walan A. Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1978; 1: 403–6
- Ricardo-Campbell R, Eisman M, Wardell W W, Crossley R. Preliminary methodology for controlled cost-benefit study of drug impact: the effect of cimetidine on days of work lost in a short-term clinical trial in duodenal ulcer. J Clin Gastroenterol 1980; 2: 37–41